157 related articles for article (PubMed ID: 34937570)
1. Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.
Karampitsakos T; Malakounidou E; Papaioannou O; Dimakopoulou V; Zarkadi E; Katsaras M; Tsiri P; Tsirikos G; Georgiopoulou V; Oikonomou I; Davoulos C; Velissaris D; Sampsonas F; Marangos M; Akinosoglou K; Tzouvelekis A
Respir Res; 2021 Dec; 22(1):317. PubMed ID: 34937570
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 May; 397(10285):1637-1645. PubMed ID: 33933206
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
5. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
; Shankar-Hari M; Vale CL; Godolphin PJ; Fisher D; Higgins JPT; Spiga F; Savovic J; Tierney J; Baron G; Benbenishty JS; Berry LR; Broman N; Cavalcanti AB; Colman R; De Buyser SL; Derde LPG; Domingo P; Omar SF; Fernandez-Cruz A; Feuth T; Garcia F; Garcia-Vicuna R; Gonzalez-Alvaro I; Gordon AC; Haynes R; Hermine O; Horby PW; Horick NK; Kumar K; Lambrecht BN; Landray MJ; Leal L; Lederer DJ; Lorenzi E; Mariette X; Merchante N; Misnan NA; Mohan SV; Nivens MC; Oksi J; Perez-Molina JA; Pizov R; Porcher R; Postma S; Rajasuriar R; Ramanan AV; Ravaud P; Reid PD; Rutgers A; Sancho-Lopez A; Seto TB; Sivapalasingam S; Soin AS; Staplin N; Stone JH; Strohbehn GW; Sunden-Cullberg J; Torre-Cisneros J; Tsai LW; van Hoogstraten H; van Meerten T; Veiga VC; Westerweel PE; Murthy S; Diaz JV; Marshall JC; Sterne JAC
JAMA; 2021 Aug; 326(6):499-518. PubMed ID: 34228774
[TBL] [Abstract][Full Text] [Related]
6. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
Karampitsakos T; Papaioannou O; Tsiri P; Katsaras M; Katsimpris A; Kalogeropoulos AP; Malakounidou E; Zarkadi E; Tsirikos G; Georgiopoulou V; Sotiropoulou V; Koulousousa E; Chourpiliadi C; Matsioulas A; Lagadinou M; Sampsonas F; Akinosoglou K; Marangos M; Tzouvelekis A
Clin Microbiol Infect; 2023 Mar; 29(3):372-378. PubMed ID: 36273769
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
Soin AS; Kumar K; Choudhary NS; Sharma P; Mehta Y; Kataria S; Govil D; Deswal V; Chaudhry D; Singh PK; Gupta A; Agarwal V; Kumar S; Sangle SA; Chawla R; Narreddy S; Pandit R; Mishra V; Goel M; Ramanan AV
Lancet Respir Med; 2021 May; 9(5):511-521. PubMed ID: 33676589
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.
Hill JA; Menon MP; Dhanireddy S; Wurfel MM; Green M; Jain R; Chan JD; Huang J; Bethune D; Turtle C; Johnston C; Xie H; Leisenring WM; Nina Kim H; Cheng GS
J Med Virol; 2021 Apr; 93(4):2270-2280. PubMed ID: 33200828
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
[TBL] [Abstract][Full Text] [Related]
14. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
Veiga VC; Prats JAGG; Farias DLC; Rosa RG; Dourado LK; Zampieri FG; Machado FR; Lopes RD; Berwanger O; Azevedo LCP; Avezum Á; Lisboa TC; Rojas SSO; Coelho JC; Leite RT; Carvalho JC; Andrade LEC; Sandes AF; Pintão MCT; Castro CG; Santos SV; de Almeida TML; Costa AN; Gebara OCE; de Freitas FGR; Pacheco ES; Machado DJB; Martin J; Conceição FG; Siqueira SRR; Damiani LP; Ishihara LM; Schneider D; de Souza D; Cavalcanti AB; Scheinberg P;
BMJ; 2021 Jan; 372():n84. PubMed ID: 33472855
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
[TBL] [Abstract][Full Text] [Related]
16. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the Effects of Tocilizumab Use on Oxygen Parameters, Inflammatory Markers and Survival in Patients Diagnosed with COVID-19 in Intensive Care Unit].
Yılmaz B; Doğan M; Ergut Sezer B
Mikrobiyol Bul; 2023 Jan; 57(1):97-107. PubMed ID: 36636849
[TBL] [Abstract][Full Text] [Related]
18. Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis.
Steuber TD; Rosandich T; Cadwallader T; Steil L; Belk M; Yendrapalli U; Hassoun A; Edwards J
Ann Pharmacother; 2024 Apr; 58(4):391-397. PubMed ID: 37522616
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
Salama C; Han J; Yau L; Reiss WG; Kramer B; Neidhart JD; Criner GJ; Kaplan-Lewis E; Baden R; Pandit L; Cameron ML; Garcia-Diaz J; Chávez V; Mekebeb-Reuter M; Lima de Menezes F; Shah R; González-Lara MF; Assman B; Freedman J; Mohan SV
N Engl J Med; 2021 Jan; 384(1):20-30. PubMed ID: 33332779
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
